IP Library › Granted Patent US 10,787,498
Granted Patent B2
US 10,787,498 · App. 14/766,036 · Granted Sep 29, 2020

Fibronectin type III domain proteins with enhanced solubility

Inventors: Aaron P Yamniuk (Lawrenceville, NJ); Stanley R Krystek (Ringoes, NJ)
Assignee: BRISTOL-MYERS SQUIBB COMPANY
C07K14/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,787,498
App. No.
14/766,036
Granted
Sep 29, 2020
Kind
B2
Abstract

Provided herein are polypeptides comprising a modified fibronectin type III (Fn3) domain, wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is mutated, and wherein the solubility is enhanced relative to the solubility of a Fn3 domain in which the amino acid corresponding to residue 58 of SEQ ID NO: 1 is not mutated. Also provided are libraries comprising a plurality of the polypeptides and a method for identifying a polypeptide that binds to a target.

Claims (11)

1. A polypeptide comprising a 10 th human fibronectin type III ( 10 Fn3) domain comprising AB, BC, CD, DE, EF and FG loops, wherein the 10 Fn3 domain comprises:

(a) AB, CD and EF loops comprising amino acid sequences corresponding to the amino acid sequence of the AB, CD and EF loops of SEQ ID NO: 1, respectively;

(b) one or more amino acid substitutions in

(i) the BC loop corresponding to amino acids 23-31 of SEQ ID NO: 1,

(ii) the DE loop corresponding to amino acids 51-56 of SEQ ID NO: 1,

(iii) the FG loop corresponding to amino acids 75-87 of SEQ ID NO: 1, or

(iv) a combination of two or more of the BC, DE and FG loops; and

(c) Glu (E) at the position corresponding to residue 58 of SEQ ID NO: 1,

wherein the solubility of the 10 Fn3 domain is enhanced relative to the solubility of the same 10 Fn3 domain wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is Thr (T), and wherein solubility of the polypeptide is determined using an ammonium sulfate solubility assay.

2. The polypeptide of claim 1 , wherein 10 Fn3 domain comprises a BC loop which has the amino acid sequence of the corresponding BC loop of the wildtype human 10 Fn3 domain (SEQ ID NO:1).

3. The polypeptide of claim 1 , wherein the DE loop of the 10 Fn3 domain is hydrophobic.

Continuity (2)
Provisional Application 61761452 · Feb 6, 2013
Related Publication 20150368319A1 · Dec 24, 2015